Mitochondria perform two critical functions in the cell, namely the production of more than 90% of the cell’s energy, and the control of cell survival as an integral part of programmed cell death (apoptosis). Unwanted changes in either of these functions can have dire consequences. Every year a significant percentage of experimental drugs at various stages of clinical development are terminated due to adverse effects that were not discovered during preclinical testing. Often, these are cardio and hepatotoxic effects caused by mitochondrial dysfunction.
Evaluation of mitochondrial toxicity early in the drug development process can reduce attrition in later clinical studies, saving time and money. BioDuro has established two robust mitochondrial toxicity evaluation assays to assess drug-induced cytotoxic effects on mitochondria in the early drug discovery process. Both assays are performed in 384-well format with low cost and high throughput.